Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Saquinavir:MCnc:Pt:Ser/Plas:Qn

Known as: Saquinavir:Mass Concentration:Point in time:Serum/Plasma:Quantitative, Saquinavir [Mass/volume] in Serum or Plasma, Saquinavir:MCnc:Pt:Sor/Plas:Qn 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
BACKGROUND A saquinavir/ritonavir-containing regimen is one option for the prevention of mother-to-child transmission of HIV… Expand
  • table 1
  • figure 1
  • table 2
Highly Cited
2005
Highly Cited
2005
Objective: To assess the pharmacokinetics and 24-week efficacy and safety of dual boosted saquinavir/lopinavir/ritonavir… Expand
2005
2005
Objectives:To assess the efficacy and safety of a once-daily regimen with didanosine, lamivudine, saquinavir, and low-dose… Expand
Review
2003
Review
2003
UNLABELLED Protease inhibitor boosting involves concurrent administration of a protease inhibitor, such as saquinavir, plus a… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • table III
2001
2001
Risk factors in the development of adverse reactions in HIV-1-infected patients treated with highly active antiretroviral therapy… Expand
Highly Cited
2000
Highly Cited
2000
ObjectiveTo determine the predictors of virological and clinical failure in patients receiving a protease inhibitor as part of… Expand
Highly Cited
2000
Highly Cited
2000
Objective: To assess the probability that protease inhibitor (PI) therapy might be discontinued because of adverse events (AE… Expand
Highly Cited
2000
Highly Cited
2000
ABSTRACT Human immunodeficiency virus type 1 (HIV-1) protease inhibitors have dramatically improved treatment options for HIV… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2000
Highly Cited
2000
ABSTRACT Amprenavir (Agenerase, 141-W94, VX-478) is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PRI… Expand
Highly Cited
1999
Highly Cited
1999
ObjectiveThe aim of this study was to confirm the most appropriate dosage of a new soft gelatin capsule (SGC) formulation of the… Expand